Prognostic significance of cell surface phenotype in acute lymphoblastic leukemia

Shiek Aejaz Aziz; Susheel Kumar Sharma; Iram Sabah; M Aleem Jan

doi:10.4103/2278-330X.155696

View/Download PDF

Buy Reprints

PDF

Translate this page into:

MINI SYMPOSIUM: MOLECULAR ONCOLOGY: Original Article

04 (

); 091-094

doi:

10.4103/2278-330X.155696

Prognostic significance of cell surface phenotype in acute lymphoblastic leukemia

Shiek Aejaz Aziz^1,, Susheel Kumar Sharma¹, Iram Sabah², M Aleem Jan³

1 Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir

2 Department of Clinical Pharmacology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir

3 Deaprtment of Clinical Hematology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir

*Corresponding author: Prof. Sheikh Aejaz Aziz. Saejaz2000@yahoo.co.in

Published: 2020-12-31

MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Context: To find out the phenotypic character of lymphoblasts of acute lymphoblastic leukemia (ALL) patients in our study cohort and their possible effect on the prognosis. Aims: To investigate the phenotype in ALL in our demographic population and to prognosticate various upfront current protocols employed in our hospital. Settings and Design: The study spanned over a period of 4 years with retrospective and prospective data of January 2008 through December 2011. Materials and Methods: 159 patients of all age groups were enrolled for the study, of which flow cytometry was done in 144 patients. Statistical Analysis Used: Analysis was done using the variables on SPSS (statistical package for social sciences) software on computer. Survival curves were estimated by method of Kaplan-Meir. Results: Majority of the patients were of B-cell (68.1%) and 30.6% patients were of T-cell lineage. Of these, 80.6% patients were having cALLa positivity. Complete remission (CR) was achieved in 59.1%, 16.4% relapsed, and 20.1% patients died. Conclusions: Phenotyping has become an important and integral part of diagnosis, classification, management and prognosticating in ALL. B-cell has been found to have a better survival over T-cell lymphoblastic leukemia. cALLa antigen positivity has good impact in achieving CR in only B-cell lineage, myeloid coexpression has no significant effect on the outcome. BFM (Berlin-Frankfurt-Münster) based protocols though showed a higher CR and survival vis-a-vis UKALL-XII. However, patients enrolled in former group being of low risk category and lesser in numbers cannot be compared statistically with a fair degree of confidence.

Keywords

Acknowledgment

The authors thank the patients and their families for their support, cooperation and patience. We would also like to thank the staff of the departments associated with care and management of the patients.

References

Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012;119:34-43.
Pui CH, Evans WE. Acute lumphoblastic leukemia. N. Engl J Med 1998:339:605-15.
Channa J, Shamsi T, Hashmi K. Role of immunophenotyping in diagnosis of acute leukemia. J Coll Physicians Surg Pak 2000;10:158-60.
Pui CH. Childhood leukemias. N Engl J Med 1995:332:1618-30.
Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987;316:1111-7.
Crist W, Pullen J, Boyett J, Falleta J, van Eys J, Borowitz M, et al. Acute lymphoid leukemia in adolescents: Clinical and biologic features predict a poor prognosis. A Pediatric Oncology Group study. J Clin Oncol 1988;6:34-43.
Bradstock KF, Kirk J, Grimsley PG, Kabral A, Hughes WG. Unusual immunophenotypes in acute leukaemias: Incidence and clinical correlations. Br J Haematol 1989;72:512-8.
Childs CC, Hirsch-Ginsberg C, Walters RS, Anderson BS, Reuben J, Trujillo JM, et al. Myeloid surface antigen-positive acute lymphoblastic leukemia (My + ALL): Immunophenotypic, ultrastructural, cytogenetic and molecular characteristics. Leukemia 1989;11:777-83.
Ludwig WD, Bartram CR, Harbott J, Koller U, Haas OA, Hansen-Hagge T, et al. Phenotypic and genotypic heterogeneity in infant acute leukemia I. acute lymphoblastic leukemia. Leukemia 1989;6:431-9.
Guyotat D, Campos L, Shi ZH, Charrin C, Treille D, Magaud JP, et al. Myeloid surface antigen expression in adult acute lymphoblastic leukemia. Leukemia 1990;9:664-6.
Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM, et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990;75:198-202.
Wiersma SR, Ortega J, Sobel E, Weinberg KI. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991;324:800-8.
Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993;82:343-62.
Greaves MF, Brown C, Rapson NT, Lister A. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol 1975;4:67-84.
Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-31.
Hoelzer D. High-dose chemotherapy in adult acute lymphoblastic leukemia. Semin Hematol 1991;28:84-9.
Berman E, Weiss M, Kempin S, Gee T, Bertino J, Clarkson B. Intensive therapy for adult acute lymphoblastic leukemia. Semin Hematol 1991;28:72-5.
Linker CA, Levitt LJ, O′Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report. Blood 1991;78:2814-22.
Blume KG, Forman SJ, Snyder DS, Nademanee AP, O′Donne1 MR, Fahey JL, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Transplantation 1987;43:389-92.
Weisdorf DJ, McGlave PB, Ramsay NK, Miller WJ, Nesbit ME, Woods WG, et al. Allogeneic bone marrow transplantation for acute leukemia: Comparative outcomes for adults and children. Br J Haematol 1988;69:351-8.
Tsukimoto I, Wong HY, Lampkin BC. Surface markers and prognostic factors in acute lymphoblastic leukemia. N Engl J Med 1976;294:245-8.
Chessells IM, Hardisty RM, Rapson NT, Greaves MF. Acute lymphoblastic leukaemia in children: Classification and prognosis. Lancet 1977;2:1307-9.
Borella L, Sen L, Dow LW, Casper IT. Cell differentiation antigens versus tumor-related antigens in childhood acute lymphoblastic leukemia (ALL). Clinical significance of leukemia markers. In: Thierfelder S, Rod H, Thiel E, editors. Immunological Diagnosis of Leukemias and Lymphomas. Vol. 20. Berlin: Springer-Verlag; 1977. p. 77 -86.

Fulltext Views
41

PDF downloads
5

View/Download PDF
Download Citations

BibTeX
RIS

Show Sections

[1] Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012;119:34-43.

[2] Pui CH, Evans WE. Acute lumphoblastic leukemia. N. Engl J Med 1998:339:605-15.

[3] Channa J, Shamsi T, Hashmi K. Role of immunophenotyping in diagnosis of acute leukemia. J Coll Physicians Surg Pak 2000;10:158-60.

[4] Pui CH. Childhood leukemias. N Engl J Med 1995:332:1618-30.

[5] Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987;316:1111-7.

[6] Crist W, Pullen J, Boyett J, Falleta J, van Eys J, Borowitz M, et al. Acute lymphoid leukemia in adolescents: Clinical and biologic features predict a poor prognosis. A Pediatric Oncology Group study. J Clin Oncol 1988;6:34-43.

[7] Bradstock KF, Kirk J, Grimsley PG, Kabral A, Hughes WG. Unusual immunophenotypes in acute leukaemias: Incidence and clinical correlations. Br J Haematol 1989;72:512-8.

[8] Childs CC, Hirsch-Ginsberg C, Walters RS, Anderson BS, Reuben J, Trujillo JM, et al. Myeloid surface antigen-positive acute lymphoblastic leukemia (My + ALL): Immunophenotypic, ultrastructural, cytogenetic and molecular characteristics. Leukemia 1989;11:777-83.

[9] Ludwig WD, Bartram CR, Harbott J, Koller U, Haas OA, Hansen-Hagge T, et al. Phenotypic and genotypic heterogeneity in infant acute leukemia I. acute lymphoblastic leukemia. Leukemia 1989;6:431-9.

[10] Guyotat D, Campos L, Shi ZH, Charrin C, Treille D, Magaud JP, et al. Myeloid surface antigen expression in adult acute lymphoblastic leukemia. Leukemia 1990;9:664-6.

[11] Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM, et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990;75:198-202.

[12] Wiersma SR, Ortega J, Sobel E, Weinberg KI. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991;324:800-8.

[13] Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993;82:343-62.

[14] Greaves MF, Brown C, Rapson NT, Lister A. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol 1975;4:67-84.

[15] Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-31.

[16] Hoelzer D. High-dose chemotherapy in adult acute lymphoblastic leukemia. Semin Hematol 1991;28:84-9.

[17] Berman E, Weiss M, Kempin S, Gee T, Bertino J, Clarkson B. Intensive therapy for adult acute lymphoblastic leukemia. Semin Hematol 1991;28:72-5.

[18] Linker CA, Levitt LJ, O′Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report. Blood 1991;78:2814-22.

[19] Blume KG, Forman SJ, Snyder DS, Nademanee AP, O′Donne1 MR, Fahey JL, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Transplantation 1987;43:389-92.

[20] Weisdorf DJ, McGlave PB, Ramsay NK, Miller WJ, Nesbit ME, Woods WG, et al. Allogeneic bone marrow transplantation for acute leukemia: Comparative outcomes for adults and children. Br J Haematol 1988;69:351-8.

[21] Tsukimoto I, Wong HY, Lampkin BC. Surface markers and prognostic factors in acute lymphoblastic leukemia. N Engl J Med 1976;294:245-8.

[22] Chessells IM, Hardisty RM, Rapson NT, Greaves MF. Acute lymphoblastic leukaemia in children: Classification and prognosis. Lancet 1977;2:1307-9.

[23] Borella L, Sen L, Dow LW, Casper IT. Cell differentiation antigens versus tumor-related antigens in childhood acute lymphoblastic leukemia (ALL). Clinical significance of leukemia markers. In: Thierfelder S, Rod H, Thiel E, editors. Immunological Diagnosis of Leukemias and Lymphomas. Vol. 20. Berlin: Springer-Verlag; 1977. p. 77 -86.

Prognostic significance of cell surface phenotype in acute lymphoblastic leukemia

Abstract

Abstract

Keywords

Acknowledgment

References

Suggested read for related articles:

We value your privacy